CA3186668A1 - Quinolines that modulate serca and their use for treating disease - Google Patents
Quinolines that modulate serca and their use for treating diseaseInfo
- Publication number
- CA3186668A1 CA3186668A1 CA3186668A CA3186668A CA3186668A1 CA 3186668 A1 CA3186668 A1 CA 3186668A1 CA 3186668 A CA3186668 A CA 3186668A CA 3186668 A CA3186668 A CA 3186668A CA 3186668 A1 CA3186668 A1 CA 3186668A1
- Authority
- CA
- Canada
- Prior art keywords
- mmol
- compound
- mixture
- water
- dichloromethane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/932,832 US20200347038A1 (en) | 2014-08-29 | 2020-07-20 | Quinolines that modulate serca and their use for treating disease |
| US16/932,832 | 2020-07-20 | ||
| PCT/US2021/042235 WO2022020261A1 (en) | 2020-07-20 | 2021-07-19 | Quinolines that modulate serca and their use for treating disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3186668A1 true CA3186668A1 (en) | 2022-01-27 |
Family
ID=79729478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3186668A Pending CA3186668A1 (en) | 2020-07-20 | 2021-07-19 | Quinolines that modulate serca and their use for treating disease |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4037685B9 (enExample) |
| JP (1) | JP7705445B2 (enExample) |
| CN (1) | CN116744928A (enExample) |
| CA (1) | CA3186668A1 (enExample) |
| DK (1) | DK4037685T3 (enExample) |
| ES (1) | ES2968041T3 (enExample) |
| FI (1) | FI4037685T3 (enExample) |
| HU (1) | HUE064550T2 (enExample) |
| PL (1) | PL4037685T3 (enExample) |
| PT (1) | PT4037685T (enExample) |
| WO (1) | WO2022020261A1 (enExample) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101784533B (zh) * | 2007-08-22 | 2013-08-21 | 艾博特股份有限两合公司 | 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途 |
| CN104302640A (zh) * | 2012-03-16 | 2015-01-21 | 埃克希金医药品有限公司 | 3,5-二氨基吡唑激酶抑制剂 |
| US10772881B2 (en) * | 2017-02-27 | 2020-09-15 | Russell Dahl | Quinolines that modulate SERCA and their use for treating disease |
| US20170281611A1 (en) * | 2014-08-29 | 2017-10-05 | Eiger Biopharmaceuticals, Inc. | Quinolines and their use for treating endoplasmic reticulum stress-caused diseases |
| US20200347038A1 (en) * | 2014-08-29 | 2020-11-05 | Russell Dahl | Quinolines that modulate serca and their use for treating disease |
| CN106966973A (zh) * | 2017-05-18 | 2017-07-21 | 湖北工业大学 | N‑苯基‑n‑（2‑甲基‑8‑喹啉基）苯甲酰胺的制备方法 |
-
2021
- 2021-07-19 CA CA3186668A patent/CA3186668A1/en active Pending
- 2021-07-19 CN CN202180063849.1A patent/CN116744928A/zh active Pending
- 2021-07-19 PT PT218458321T patent/PT4037685T/pt unknown
- 2021-07-19 PL PL21845832.1T patent/PL4037685T3/pl unknown
- 2021-07-19 EP EP21845832.1A patent/EP4037685B9/en active Active
- 2021-07-19 DK DK21845832.1T patent/DK4037685T3/da active
- 2021-07-19 JP JP2023504102A patent/JP7705445B2/ja active Active
- 2021-07-19 ES ES21845832T patent/ES2968041T3/es active Active
- 2021-07-19 WO PCT/US2021/042235 patent/WO2022020261A1/en not_active Ceased
- 2021-07-19 HU HUE21845832A patent/HUE064550T2/hu unknown
- 2021-07-19 FI FIEP21845832.1T patent/FI4037685T3/fi active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022020261A1 (en) | 2022-01-27 |
| JP7705445B2 (ja) | 2025-07-09 |
| FI4037685T3 (fi) | 2023-11-27 |
| EP4037685A4 (en) | 2022-11-30 |
| DK4037685T3 (en) | 2024-01-02 |
| EP4037685B1 (en) | 2023-09-20 |
| WO2022020261A9 (en) | 2022-09-09 |
| ES2968041T3 (es) | 2024-05-06 |
| CN116744928A (zh) | 2023-09-12 |
| PT4037685T (pt) | 2023-12-28 |
| HUE064550T2 (hu) | 2024-03-28 |
| EP4037685B9 (en) | 2024-03-06 |
| PL4037685T3 (pl) | 2024-04-02 |
| JP2023534992A (ja) | 2023-08-15 |
| EP4037685A1 (en) | 2022-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12144806B2 (en) | Quinolines that modulate SERCA and their use for treating disease | |
| ES2972487T3 (es) | Formas sólidas de un inhibidor de tienopirimidindiona acc y métodos para la producción del mismo | |
| ES2891734T3 (es) | Derivados de bencimidazol como inhibidores de tirosina quinasa ERBB para el tratamiento del cáncer | |
| AU2015231215B2 (en) | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | |
| US20170281611A1 (en) | Quinolines and their use for treating endoplasmic reticulum stress-caused diseases | |
| EP3174859A1 (en) | Flt3 receptor antagonists | |
| US10383867B2 (en) | Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders | |
| US11827626B2 (en) | Quinolines that modulate SERCA and their use for treating disease | |
| US10772881B2 (en) | Quinolines that modulate SERCA and their use for treating disease | |
| US10383868B2 (en) | Quinoline containing compounds and their use for treating endoplasmic reticulum stress-related diseases | |
| TWI473793B (zh) | 芳基磺醯胺ｃｃｒ３拮抗劑 | |
| EP4037685B1 (en) | Quinoline that modulate serca and its use for treating disease | |
| JP6450010B2 (ja) | ３，５−ジアミノピラゾールキナーゼ阻害剤 | |
| HK40099648A (en) | Quinolines that modulate serca and their use for treating disease | |
| US20210269404A1 (en) | Quinoline amines useful as cytoprotective agents | |
| US20210323924A1 (en) | Quinoline sulfonamides useful to treat disease | |
| US10730843B1 (en) | Quinoxalines useful as cytoprotective agents | |
| US10730839B2 (en) | Quinolines as cytoprotective agents | |
| US10793558B2 (en) | Quinoline oxadiazoles as cytoprotective agents | |
| US10800766B2 (en) | Quinoline alkenes as cytoprotective agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250711 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250711 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250716 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250716 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250716 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250717 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250924 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250924 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250924 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250924 |